RHOJ Induces Epithelial-to-Mesenchymal Transition by IL-6/STAT3 to Promote Invasion and Metastasis in Gastric Cancer

Conclusions: These results indicate that the upregulation of RHOJ contributes to EMT-subtype GC invasion and metastasis via IL-6/STAT3 signaling, and RHOJ is expected to become a promising biomarker and therapeutic target for EMT-subtype GC patients.

[1]  Akiyoshi Uemura,et al.  RHOJ controls EMT-associated resistance to chemotherapy , 2023, Nature.

[2]  Wei Wang,et al.  Standardizing the classification of gastric cancer patients with limited and adequate number of retrieved lymph nodes: an externally validated approach using real-world data , 2022, Military Medical Research.

[3]  Min Qi,et al.  RhoJ facilitates angiogenesis in glioblastoma via JNK/VEGFR2 mediated activation of PAK and ERK signaling pathways , 2022, International journal of biological sciences.

[4]  V. Sanz-Moreno,et al.  RhoGTPase Signalling in Cancer Progression and Dissemination. , 2021, Physiological reviews.

[5]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[6]  H. Xia,et al.  Rhoj Is a Novel Target for Progression and Invasion of Glioblastoma by Impairing Cytoskeleton Dynamics , 2020, Neurotherapeutics.

[7]  Wei Liu,et al.  Cancer-associated Fibroblasts induce epithelial-mesenchymal transition via the Transglutaminase 2-dependent IL-6/IL6R/STAT3 axis in Hepatocellular Carcinoma , 2020, International journal of biological sciences.

[8]  G. Serini,et al.  Angiogenesis: The Importance of RHOJ-Mediated Trafficking of Active Integrins , 2020, Current Biology.

[9]  Akiyoshi Uemura,et al.  RhoJ integrates attractive and repulsive cues in directional migration of endothelial cells , 2020, The EMBO journal.

[10]  Aimin Li,et al.  CPEB3 inhibits epithelial-mesenchymal transition by disrupting the crosstalk between colorectal cancer cells and tumor-associated macrophages via IL-6R/STAT3 signaling , 2020, Journal of experimental & clinical cancer research : CR.

[11]  A. Gavin,et al.  Progress in cancer survival, mortality, and incidence in seven high-income countries 1995-2014 (ICBP SURVMARK-2): a population-based study. , 2019, The Lancet. Oncology.

[12]  R. Salazar,et al.  Comparison and applicability of molecular classifications for gastric cancer. , 2019, Cancer treatment reviews.

[13]  W. Jin,et al.  MEST induces Twist-1-mediated EMT through STAT3 activation in breast cancers , 2019, Cell Death & Differentiation.

[14]  C. Blanpain,et al.  EMT Transition States during Tumor Progression and Metastasis. , 2019, Trends in cell biology.

[15]  Kristina M. Ilieva,et al.  Regional Activation of Myosin II in Cancer Cells Drives Tumor Progression via a Secretory Cross-Talk with the Immune Microenvironment , 2019, Cell.

[16]  T. Voet,et al.  Identification of the tumour transition states occurring during EMT , 2018, Nature.

[17]  Melissa Matz,et al.  Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries , 2018, The Lancet.

[18]  Asfar S Azmi,et al.  Rho GTPase effectors and NAD metabolism in cancer immune suppression , 2018, Expert opinion on therapeutic targets.

[19]  Dahai Yu,et al.  IL-6 promotes epithelial-to-mesenchymal transition of human peritoneal mesothelial cells possibly through the JAK2/STAT3 signaling pathway. , 2017, American journal of physiology. Renal physiology.

[20]  W. Pavan,et al.  The RhoJ-BAD signaling network: An Achilles’ heel for BRAF mutant melanomas , 2017, PLoS genetics.

[21]  Jing Yang,et al.  Epithelial–mesenchymal transition in tumor metastasis , 2016, Molecular oncology.

[22]  A. Ridley,et al.  Regulating Rho GTPases and their regulators , 2016, Nature Reviews Molecular Cell Biology.

[23]  D. Iliopoulos,et al.  Diminished expression of CRHR2 in human colon cancer promotes tumor growth and EMT via persistent IL-6/Stat3 signaling. , 2015, Cellular and molecular gastroenterology and hepatology.

[24]  B. Shen,et al.  Long noncoding RNA lncTCF7, induced by IL-6/STAT3 transactivation, promotes hepatocellular carcinoma aggressiveness through epithelial-mesenchymal transition , 2015, Journal of Experimental & Clinical Cancer Research.

[25]  Jason G. Jin,et al.  Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes , 2015, Nature Medicine.

[26]  D. Lodygin,et al.  Corrigendum. IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis. , 2015, The Journal of clinical investigation.

[27]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of gastric adenocarcinoma , 2014, Nature.

[28]  D. Lodygin,et al.  IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis. , 2014, The Journal of clinical investigation.

[29]  Doheon Lee,et al.  Vascular RhoJ is an effective and selective target for tumor angiogenesis and vascular disruption. , 2014, Cancer cell.

[30]  G. Christofori,et al.  VEGF-mediated angiogenesis links EMT-induced cancer stemness to tumor initiation. , 2014, Cancer research.

[31]  M. Nieto.  Epithelial Plasticity: A Common Theme in Embryonic and Cancer Cells , 2013, Science.

[32]  A. Ganesan,et al.  RhoJ regulates melanoma chemoresistance by suppressing pathways that sense DNA damage. , 2012, Cancer research.

[33]  J. Kim,et al.  Bio-inspired design and potential biomedical applications of a novel class of high-affinity peptides. , 2012, Angewandte Chemie.

[34]  M. Nieto,et al.  The ins and outs of the epithelial to mesenchymal transition in health and disease. , 2011, Annual review of cell and developmental biology.

[35]  Amber N. Stratman,et al.  RhoJ is an endothelial cell-restricted Rho GTPase that mediates vascular morphogenesis and is regulated by the transcription factor ERG. , 2011, Blood.

[36]  C. Marshall,et al.  RhoJ/TCL Regulates Endothelial Motility and Tube Formation and Modulates Actomyosin Contractility and Focal Adhesion Numbers , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[37]  Mingyao Liu,et al.  Morelloflavone, a biflavonoid, inhibits tumor angiogenesis by targeting rho GTPases and extracellular signal-regulated kinase signaling pathways. , 2009, Cancer research.

[38]  A. Ridley.  Rho GTPases and actin dynamics in membrane protrusions and vesicle trafficking. , 2006, Trends in cell biology.

[39]  A. Brasier,et al.  RhoA Mediates Angiotensin II–Induced Phospho-Ser536 Nuclear Factor &kgr;B/RelA Subunit Exchange on the Interleukin-6 Promoter in VSMCs , 2006, Circulation research.

[40]  Sofia D. Merajver,et al.  Multifaceted Role of Rho Proteins in Angiogenesis , 2005, Journal of Mammary Gland Biology and Neoplasia.

[41]  Krister Wennerberg,et al.  Rho and Rac Take Center Stage , 2004, Cell.

[42]  A. Hall,et al.  Rho GTPases in cell biology , 2002, Nature.

[43]  C. Pothoulakis,et al.  Substance P-stimulated interleukin-8 expression in human colonic epithelial cells involves Rho family small GTPases. , 2002, The Biochemical journal.

[44]  B. Kaina,et al.  Rho GTPases in human breast tumours: expression and mutation analyses and correlation with clinical parameters , 2002, British Journal of Cancer.

[45]  S. Kuroda,et al.  Rac1 and Cdc42 Capture Microtubules through IQGAP1 and CLIP-170 , 2002, Cell.

[46]  N. Suttorp,et al.  Rho proteins and the p38-MAPK pathway are important mediators for LPS-induced interleukin-8 expression in human endothelial cells. , 2000, Blood.

[47]  J. Redondo,et al.  Pyrrolidine dithiocarbamate inhibits the production of interleukin-6, interleukin-8, and granulocyte-macrophage colony-stimulating factor by human endothelial cells in response to inflammatory mediators: modulation of NF-kappa B and AP-1 transcription factors activity. , 1996, Blood.

[48]  L. R. Macfarlane,et al.  Department of pathology , 1961, Journal of the Royal Army Medical Corps.